LIPOCINE INC. (NASDAQ:LPCN) Files An 8-K Other Events

LIPOCINE INC. (NASDAQ:LPCN) Files An 8-K Other Events
Item 8.01 Other Events

On March 13, 2020, the Company issued a press release announcing financial and operational results for the year ended December 31, 2019. The press release is filed as Exhibit 99.1 and is incorporated herein by reference.

The Company has updated its corporate presentation that it uses when meeting with investors, analysts and others. The presentation is filed as Exhibit 99.2.

Item 9.01 Financial Statements and Exhibits.

(d)       Exhibits

The following exhibits are filed with this report:

99.1 Press Release announcing Financial and Operational Results for the Year Ended December 31, 2019
99.2 Corporate Presentation


Lipocine Inc. Exhibit
EX-99.1 2 tm2012454d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1     Lipocine Announces 2019 Year End Financial and Operational Results   SALT LAKE CITY,…
To view the full exhibit click here

Story continues below

About LIPOCINE INC. (NASDAQ:LPCN)

Lipocine Inc. is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs. Its lead product candidate, LPCN 1021, is an oral testosterone replacement therapy (TRT), designed for twice-a-day dosing and is in Phase III testing. The Company’s additional pipeline candidates include LPCN 1111, an oral testosterone therapy product targeted for once daily dosing, which is in Phase II testing, and LPCN 1107, an oral therapy for the prevention of preterm birth, which is in Phase I testing. These products are based on its Lip’ral promicellar drug delivery technology platform. Lip’ral promicellar technology is a technology based on lipidic compositions, which form an optimal dispersed phase in the gastrointestinal environment for improved absorption of insoluble drugs.

An ad to help with our costs